000			03998nam a22003255i 4500
999			_c403043 _d403043
001			403043
003			ES-MaUEC
005			20240712103809.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			240319s2023 si | o |||| 0|eng d
020			_a9789819971411
024	7		_a10.1007/978-981-99-7141-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .L8 _b2023 EB
245	0	0	_aImmunotherapy Against Lung Cancer : _bEmerging Opportunities and Challenges _cedited by Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua
250			_a1st ed. 2023
264		1	_aSingapore _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aChapter 1_An introduction to Lung cancer -- Chapter 2_Immunobiology of Lung cancer -- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy -- Chapter 4_Recent advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer -- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer -- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer -- Chapter 9_IDO and TGF-{esc}(Sb{esc}(B inhibitors for the treatment of Lung cancer -- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer -- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer -- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer.-Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer -- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy -- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer -- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer -- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer -- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer.
520			_aThis book provides insight into the various immunotherapeutic approaches for the treatment of lung cancers. The chapters of the book discuss the detailed mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive environment, and various vaccines for lung cancer. A chapter of the book explores the recent applications of the oncolytic virus in lung cancer treatment and discusses the potential and direction of oncolytic virus-based therapeutic vaccines. The chapter also elucidates the current understanding of the role of Toll-Like Receptors (TLRs) in tumor progression, and the recent progress in utilizing TLR agonists as potential therapeutic agents in lung cancer treatment. Towards the end, the book reviews the applications of stereotactic body radiation therapy (SBRT) and immunotherapy for the treatment of lung cancer. This book provides useful information to a range of audiences including clinical researchers working in the field of lung cancer, and undergraduate and postgraduate students from various disciplines such as pharmacy, microbiology, immunology, pharmacology, biotechnology, and health sciences.
988			_aSpringer_Medicine_2023
650		7	_2embne _9168954 _aPulmones _xCáncer
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-99-7141-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2024 _dz _eu _zSI